Part II: Public Payers in the U.S. & Key International Markets

October 3, 2019 4:00 PM - 6:30 PM

MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139

This event, Part II in a three part series that will explore the value of health, will focus on Medicare and Medicaid in the U.S., existing access and reimbursement issues for innovative therapies and cures, proposed changes to those programs that could impact access and reimbursement, and barriers that exist to innovative payment models. The event will also consider those key international models of assessing value and determining access, how the global landscape is shifting, what the U.S. may be able to learn from them, and highlight emerging markets like China that are moving toward the realm of “must consider” when developing an international strategy. Speakers will share lessons learned and case studies around:

  • How Louisiana Medicaid cured its Hepatitis C population through an innovative payment model with Gilead Sciences 
  • How Biogen and Alnylam approached approvals abroad; lessons learned for navigating health technology assessment (HTA) consolidation in Europe
  • Why a US biotech partnered with a Chinese company to reach the large patient populations in China

We believe this issue is especially timely. We’re at an inflection point, with science that’s been tested for decades finally becoming a reality for patients and a payer system that has not caught up with this level of innovation. Myriad factors are combining to alter the status quo – with policymakers demanding action, and healthcare stakeholders agreeing that we must come up with real solutions. If we don’t come together and address the value equation as an industry and ensure patient access to all new therapies, government or other stakeholders will – and they will likely get it wrong. Download the Part II whitepaper

Drinks and appetizers will be provided. If you're not a MassBio member but are interested in attending, please email

Sr. Director, Head of Strategy and Operations US Market Access & Reimbursement (MA&R), Biogen
Elizabeth has been with Biogen since 2012 and currently leads the US Market Access Strategy and Operations team. Her team is responsible for ensuring market access strategy for Biogen’s marketed products and late-stage pipeline align with corporate goals. Prior to joining the US team, Elizabeth lead the market access team for Multiple Sclerosis responsible for Europe and Canada. During this time, her team launched 4 products and lead over 40 reimbursement re-assessments in the region. She began her career at Biogen leading Health Economics and Outcomes Research for the Interferon portfolio. Prior to joining Biogen, Elizabeth’s early career was in both health economic consulting supporting health technology assessments and market access strategy. During this time, she worked on over 15 product launches. She also worked at the Centers for Medicare and Medicaid Services (CMS) during the implementation of the Medicare Modernization Act. Elizabeth eared a PhD in Health Economics and a Master’s in Health Policy from the Bloomberg School of Public Health at The Johns Hopkins University. She holds a dual BA from Smith College in Economics and German Literature and is fluent in German.